Quantcast

Latest Protein kinase inhibitor Stories

2011-07-01 06:54:20

(Ivanhoe Newswire) "“ A new study reveals that cancer patients treated with the drugs sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared. "The damage that chemotherapy does to normal, healthy cells as it treats cancer has been well documented, but the precise effect that the new class of targeted agents has on the immune system is less well known. This study helps us answer that question," Keith...

2011-06-29 12:12:54

Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research. Keith Flaherty, M.D., director of developmental therapeutics at the Massachusetts General Hospital and a senior editor of Clinical Cancer Research, said the findings have broad implications beyond questions of patient...

2011-06-23 06:22:00

DALLAS, June 23, 2011 /PRNewswire/ -- - ReportsnReports announces it will carry 'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies'Report in its store Browse the complete 'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies [http://www.reportsnreports.com/reports/89350-multitargeted-therapies-promiscuous-drugs-and-combination-therap.html ] 'Report now! Search 75000+ Market Research Reports [http://www.reportsnreports.com ]...

2011-05-25 11:28:00

RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed...

2011-05-19 06:00:00

ROCKVILLE, Md., May 19, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. The data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3 - 7, 2011 in Chicago, Illinois. (Logo:...

2011-04-25 13:50:00

WEST PALM BEACH, Fla., April 25, 2011 /PRNewswire/ -- The ophthalmic therapeutics company Xcovery Vision announced today that Sheridan G. Snyder, OBE, Chairman and CEO, and Dr. Ken Mandell, President and COO, will be speaking at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale Florida, May 1-5, 2011. Mr. Snyder's talk Perspective of a Serial Entrepreneur recounts his repeated success as founder of multiple biotech companies that include...

2011-02-28 07:00:00

SINGAPORE, Feb. 28, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models. In vivo and in vitro data on SB2343 were presented at American Association of Cancer Research (AACR) Special Conference on Targeting PI3K/mTOR Signaling in Cancer held in San Francisco. SB2343 is...

2011-02-22 07:37:00

SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the execution of a definitive agreement relating to the collaborative research, development and commercialization of Proacta's PR509, a hypoxia-activated pro-drug for the treatment of cancer. (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-a ) (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b ) "We have worked diligently to arrive at this...

2010-12-09 07:45:00

RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation.(1) The updated LUX-Lung 1 data will be presented at...

2010-12-08 08:00:00

RIDGEFIELD, Conn. Dec. 8, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of a phase III clinical trial in the United States to investigate one of its oncology pipeline compounds, afatinib* (BIBW 2992), for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2)...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related